A Phase 1 Trial of a Novel XPO1 Inhibitor in Patients With Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
Study SL-801-0115 is a dose-escalation study evaluating multiple doses and schedules of
orally administered SL-801 in patients with Advanced Solid Tumors